Hospital
RCHP Billings - Missoula LLC
RCHP Billings - Missoula LLC was paid $4.01M by Medicaid between Jan 2018 and Dec 2024, across 334 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoRCHP BILLINGS - MISSOULA LLC
MISSOULA, MT 59804
MISSOULA, MT 59804
33aNPI1346642899assigned 09/16/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.01M
24GClaims833,786
24DCodes billed334
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Montana
Rank by total paid#1 of 10
Median peer was paid$774K
This provider vs. median5.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 132,440 | $541K | |
| 2019 | 121,543 | $569K | |
| 2020 | 108,000 | $414K | |
| 2021 | 128,135 | $562K | |
| 2022 | 130,183 | $647K | |
| 2023 | 122,466 | $670K | |
| 2024incomplete | 91,019 | $605K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 25,308 | 22,542 | $573K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.1% | 15,976 | 13,801 | $324K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.5% | 14,061 | 4,125 | $301K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 9,930 | 8,247 | $276K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 6.2% | 21,296 | 6,691 | $249K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 4,678 | 4,009 | $221K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4.4% | 3,465 | 1,781 | $175K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 23,339 | 6,489 | $161K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 3,168 | 2,746 | $74K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 2,513 | 2,327 | $66K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 1,115 | 913 | $65K |
| J3490 | Unclassified drugs | 1.5% | 15,992 | 7,897 | $60K |
322 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 9,864 | $57K |
| 80053 | Comprehensive metabolic panel | 1.4% | 38,390 | $57K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.4% | 450 | $55K |
| G0378 | Hospital observation service, per hour | 1.3% | 1,481 | $53K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.3% | 982 | $53K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.2% | 8,060 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 39,795 | $43K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 13,385 | $43K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 5,348 | $41K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 742 | $36K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 754 | $35K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,315 | $29K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,949 | $27K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 311 | $24K |
| 86140 | <1% | 4,027 | $24K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,508 | $22K |
| 74018 | <1% | 1,466 | $21K | |
| 97161 | <1% | 1,887 | $21K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,150 | $21K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,056 | $20K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,461 | $18K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 217 | $17K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,447 | $17K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,052 | $16K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 136 | $15K |
| 81001 | <1% | 17,966 | $15K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,905 | $15K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,741 | $14K |
| 84703 | <1% | 4,899 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 651 | $13K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 370 | $13K |
| 92523 | <1% | 278 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,049 | $12K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,669 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,329 | $11K |
| 73610 | <1% | 943 | $11K | |
| 85027 | <1% | 12,351 | $11K | |
| 36592 | <1% | 2,043 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,772 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,378 | $10K |
| 87631 | <1% | 303 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 36,934 | $10K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,884 | $9K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,337 | $9K |
| 85651 | <1% | 2,971 | $9K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 139 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,182 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,351 | $8K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 812 | $8K |
| 83690 | <1% | 7,006 | $8K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,749 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,310 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,113 | $8K |
| 76770 | <1% | 586 | $8K | |
| 92526 | <1% | 598 | $8K | |
| 88304 | <1% | 1,367 | $8K | |
| 87486 | <1% | 774 | $7K | |
| 73630 | <1% | 1,015 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,467 | $7K |
| 87581 | <1% | 774 | $7K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 578 | $7K |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,158 | $6K |
| 93976 | <1% | 418 | $6K | |
| 96415 | <1% | 381 | $6K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 799 | $6K |
| 87081 | <1% | 2,345 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,683 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,288 | $6K |
| 82728 | <1% | 3,532 | $6K | |
| 36591 | <1% | 2,186 | $6K | |
| 73562 | <1% | 1,024 | $6K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,980 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,590 | $5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 359 | $5K |
| 73110 | <1% | 299 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,135 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,896 | $5K |
| 81025 | <1% | 4,014 | $5K | |
| 84439 | <1% | 3,621 | $5K | |
| 12001 | <1% | 220 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,316 | $5K |
| 97162 | <1% | 948 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,114 | $5K |
| 73130 | <1% | 436 | $5K | |
| 84484 | <1% | 5,401 | $4K | |
| 87186 | <1% | 3,642 | $4K | |
| 87070 | <1% | 4,498 | $4K | |
| 80076 | <1% | 1,791 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,559 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 1,612 | $4K |
| 80061 | Lipid panel | <1% | 7,850 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,436 | $4K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,643 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,505 | $3K |
| 85007 | <1% | 1,197 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,199 | $3K |
| 83540 | <1% | 2,694 | $3K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,889 | $3K |
| 83550 | <1% | 2,591 | $3K | |
| 85379 | <1% | 1,654 | $3K | |
| 59025 | Fetal non-stress test | <1% | 3,304 | $3K |
| 83735 | <1% | 5,109 | $3K | |
| 87147 | <1% | 2,872 | $2K | |
| 73030 | <1% | 489 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,563 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,487 | $2K |
| 94060 | <1% | 491 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,137 | $2K |
| 96376 | <1% | 1,639 | $2K | |
| 80320 | <1% | 867 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,610 | $2K |
| 87641 | <1% | 4,182 | $2K | |
| 99152 | <1% | 2,599 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,592 | $2K |
| 83605 | <1% | 2,114 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,105 | $2K |
| 87040 | <1% | 1,124 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,665 | $2K |
| 72141 | <1% | 385 | $2K | |
| 87077 | <1% | 2,191 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 584 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,048 | $2K |
| 88342 | <1% | 788 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,667 | $2K |
| 84702 | <1% | 2,260 | $2K | |
| 85652 | <1% | 658 | $2K | |
| 82962 | <1% | 5,131 | $2K | |
| 85730 | <1% | 1,221 | $1K | |
| 73080 | <1% | 51 | $1K | |
| 82607 | <1% | 1,479 | $1K | |
| 73090 | <1% | 43 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 334 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 875 | $1K |
| 72100 | <1% | 376 | $1K | |
| 77012 | <1% | 88 | $1K | |
| 96367 | <1% | 829 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,796 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,456 | $1K |
| 94760 | <1% | 714 | $1K | |
| 80143 | <1% | 461 | $1K | |
| 87088 | <1% | 1,161 | $1K | |
| 86141 | <1% | 296 | $1K | |
| 97116 | <1% | 2,222 | $1K | |
| 87205 | <1% | 962 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 419 | $992.37 |
| 82550 | <1% | 858 | $984.85 | |
| 84100 | <1% | 1,044 | $970.49 | |
| 85610 | <1% | 4,566 | $949.66 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 127 | $942.65 |
| D1120 | Dental cleaning, child | <1% | 47 | $895.04 |
| D0120 | Dental checkup, returning patient | <1% | 45 | $895.04 |
| 86850 | <1% | 3,495 | $856.33 | |
| 12011 | <1% | 26 | $849.99 | |
| 88307 | <1% | 528 | $844.90 | |
| 90715 | <1% | 302 | $790.08 | |
| 82570 | <1% | 2,683 | $787.28 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,706 | $780.44 |
| 82746 | <1% | 631 | $762.52 | |
| 86900 | <1% | 3,962 | $704.67 | |
| 74019 | <1% | 127 | $702.95 | |
| 83880 | <1% | 952 | $696.08 | |
| 84480 | <1% | 750 | $691.72 | |
| 29125 | <1% | 12 | $676.03 | |
| 82670 | <1% | 261 | $668.12 | |
| 80305 | <1% | 2,561 | $663.81 | |
| 84403 | <1% | 128 | $561.02 | |
| 86901 | <1% | 3,977 | $559.39 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,998 | $557.59 |
| 87210 | <1% | 2,028 | $508.48 | |
| 82077 | <1% | 604 | $498.51 | |
| 80179 | <1% | 248 | $489.10 | |
| 82565 | <1% | 494 | $487.55 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 454 | $461.59 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 513 | $453.03 |
| 93971 | <1% | 394 | $452.01 | |
| 97164 | <1% | 33 | $410.55 | |
| 86803 | <1% | 2,908 | $406.29 | |
| 83615 | <1% | 175 | $371.44 | |
| 73140 | <1% | 57 | $364.51 | |
| C1769 | Guide wire | <1% | 141 | $359.54 |
| 97760 | <1% | 626 | $351.05 | |
| 86780 | <1% | 2,166 | $339.15 | |
| 82043 | <1% | 1,364 | $334.87 | |
| G0008 | Administration of influenza virus vaccine | <1% | 216 | $321.61 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 368 | $306.20 |
| 97165 | <1% | 138 | $294.82 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 526 | $290.12 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 218 | $276.49 |
| 97803 | <1% | 20 | $272.00 | |
| 83001 | <1% | 203 | $268.67 | |
| 90686 | <1% | 691 | $256.46 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 429 | $231.96 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 607 | $212.50 |
| 86308 | <1% | 115 | $206.06 | |
| 76536 | <1% | 15 | $192.18 | |
| 82805 | <1% | 131 | $186.99 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,186 | $186.29 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,919 | $182.58 |
| 84146 | <1% | 223 | $177.61 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 213 | $175.22 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 28,171 | $169.98 |
| 84156 | <1% | 895 | $164.44 | |
| 72170 | <1% | 51 | $161.82 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,499 | $161.08 |
| 87075 | <1% | 142 | $153.85 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 3,065 | $152.43 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,282 | $143.04 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 597 | $138.34 |
| 87340 | <1% | 1,628 | $137.07 | |
| 0002A | <1% | 325 | $134.30 | |
| 0001A | <1% | 313 | $134.30 | |
| 76642 | <1% | 1,122 | $126.38 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 120 | $116.22 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 67 | $106.53 |
| 94729 | <1% | 120 | $105.87 | |
| 86787 | <1% | 657 | $95.35 | |
| 84550 | <1% | 82 | $82.73 | |
| 80069 | <1% | 1,132 | $81.92 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 14 | $78.21 |
| 83970 | <1% | 809 | $78.02 | |
| 82977 | <1% | 19 | $73.94 | |
| 86592 | <1% | 285 | $69.09 | |
| 0012A | <1% | 69 | $67.15 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 581 | $62.92 |
| 86762 | <1% | 1,114 | $61.60 | |
| 77080 | <1% | 12 | $61.56 | |
| 84520 | <1% | 29 | $60.93 | |
| 87328 | <1% | 15 | $60.10 | |
| 87329 | <1% | 15 | $60.08 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 15 | $57.38 |
| 80051 | <1% | 29 | $55.36 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,238 | $50.29 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 183 | $39.18 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 580 | $38.94 |
| 82310 | <1% | 13 | $38.80 | |
| 82784 | <1% | 44 | $35.16 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 322 | $34.36 |
| 86431 | <1% | 141 | $32.13 | |
| 84460 | <1% | 14 | $30.06 | |
| 86703 | <1% | 3,031 | $24.30 | |
| 80178 | <1% | 27 | $16.56 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,678 | $14.38 |
| 82247 | <1% | 22 | $9.49 | |
| 82950 | <1% | 1,197 | $8.97 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 1,356 | $0.00 |
| 62323 | 0% | 380 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 326 | $0.00 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 28 | $0.00 |
| 93017 | 0% | 195 | $0.00 | |
| 97163 | 0% | 82 | $0.00 | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | 0% | 13 | $0.00 |
| 71250 | 0% | 14 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 28 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 200 | $0.00 |
| 94726 | 0% | 93 | $0.00 | |
| 76942 | 0% | 205 | $0.00 | |
| 83721 | 0% | 12 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 97 | $0.00 |
| 85014 | 0% | 55 | $0.00 | |
| 77065 | Tomosynthesis, mammo | 0% | 32 | $0.00 |
| 76882 | 0% | 14 | $0.00 | |
| 77066 | Tomosynthesis, mammo | 0% | 27 | $0.00 |
| 91300 | 0% | 532 | $0.00 | |
| 97129 | 0% | 185 | $0.00 | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 0% | 15 | $0.00 |
| 90670 | 0% | 15 | $0.00 | |
| 85046 | 0% | 16 | $0.00 | |
| 87045 | 0% | 12 | $0.00 | |
| 84112 | 0% | 123 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 178 | $0.00 |
| 86200 | 0% | 14 | $0.00 | |
| 84145 | 0% | 19 | $0.00 | |
| 83003 | 0% | 31 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 37 | $0.00 |
| 73590 | 0% | 13 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 98 | $0.00 |
| 80164 | 0% | 17 | $0.00 | |
| 87400 | 0% | 206 | $0.00 | |
| 80074 | 0% | 12 | $0.00 | |
| 62321 | 0% | 50 | $0.00 | |
| 43235 | 0% | 16 | $0.00 | |
| 87899 | 0% | 23 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 20 | $0.00 |
| J2358 | Injection, olanzapine, long-acting, 1 mg | 0% | 113 | $0.00 |
| 97032 | 0% | 96 | $0.00 | |
| 87640 | 0% | 811 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 256 | $0.00 |
| 80055 | 0% | 361 | $0.00 | |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | 0% | 74 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 1,329 | $0.00 |
| 85018 | 0% | 49 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 218 | $0.00 |
| 84153 | 0% | 354 | $0.00 | |
| D1351 | Sealant - per tooth | 0% | 12 | $0.00 |
| 64483 | 0% | 226 | $0.00 | |
| 97113 | 0% | 213 | $0.00 | |
| 94761 | 0% | 185 | $0.00 | |
| 91301 | 0% | 108 | $0.00 | |
| 87015 | 0% | 17 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 577 | $0.00 |
| 36416 | 0% | 531 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 317 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 86 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,102 | $0.00 |
| A9150 | Non-prescription drugs | 0% | 32 | $0.00 |
| 97597 | 0% | 263 | $0.00 | |
| 73501 | 0% | 72 | $0.00 | |
| 81000 | 0% | 46 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 58 | $0.00 |
| H0049 | Alcohol and/or drug screening | 0% | 116 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 46 | $0.00 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 29 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 63 | $0.00 |
| 97130 | 0% | 49 | $0.00 | |
| 70491 | 0% | 14 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 55 | $0.00 |
| 0011A | 0% | 52 | $0.00 | |
| D7140 | Extraction, erupted tooth or exposed root | 0% | 12 | $0.00 |
| 70498 | 0% | 12 | $0.00 | |
| 87046 | 0% | 24 | $0.00 | |
| 84144 | 0% | 15 | $0.00 | |
| 95700 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.